Emyria Trains 31 NSW Clinicians Ahead of Sydney Clinic Launch in Q3 2026
Emyria trains first NSW clinical workforce as Sydney clinic opening nears
Emyria Limited has completed training for its first cohort of NSW-based clinicians ahead of the planned Q3 CY2026 opening of its first Sydney Empax clinic at Matilda Nepean. The company trained 25 therapists and 6 psychiatrists over the weekend, representing a foundational operational step for its fourth state-based clinical operation. These newly trained clinicians join an existing contracted workforce of more than 100 trained clinicians across Western Australia, Victoria, and Queensland.
The training milestone demonstrates execution against stated corporate milestones and operational readiness for NSW market entry.
When big ASX news breaks, our subscribers know first
What is psychedelic-assisted therapy and why does it matter?
Psychedelic-assisted therapy is an evidence-based treatment approach for mental health conditions that combines trained clinicians (therapists and psychiatrists) with emerging therapies. Emyria’s Empax model targets patients who have not found relief from conventional care, including those with PTSD and treatment-resistant depression.
PTSD remission outcomes from Emyria’s existing clinics show that two-thirds of treatment-resistant patients maintain clinical remission 12 months after completing the programme, providing the evidence base that underpins insurer and hospital partnerships as the network scales into NSW.
The clinical workforce forms a core component of Emyria’s integrated business model. For investors, the trained clinical workforce represents essential infrastructure for service delivery and scalability. Without qualified clinicians, the company cannot operate clinics or generate the patient data that underpins its therapy pipeline.
NSW represents Australia’s largest addressable patient market
NSW is Australia’s most populous state and the largest target patient market for mental health therapies. The state’s mental health demand profile creates a structural tailwind for Emyria’s expansion:
- Over 1.8 million people in NSW have a long-term mental or behavioural condition
- Psychological injuries have increased 64% since 2019-20
These figures quantify the addressable market and demonstrate the strategic rationale for NSW expansion. The growing prevalence of psychological injuries indicates sustained demand for innovative treatment options beyond conventional care pathways.
Sydney clinic operational progress on track
Alongside clinician training, Emyria is progressing multiple operational workstreams for the Sydney clinic opening. Medication has been secured, and fit-out requirements within Matilda Nepean are being finalised. The clinic will be located at Matilda Nepean and is the company’s first NSW-based Empax clinic.
The parallel progression of these operational elements reduces execution risk ahead of the Q3 CY2026 opening. Medication supply, physical infrastructure, and trained workforce must all align for a functional clinic launch.
National clinical footprint continues to expand
The NSW clinic represents Emyria’s fourth state-based clinical operation, following established centres in Western Australia, Queensland, and Victoria. The geographic expansion diversifies the company’s revenue base and positions it to serve patients across Australia’s major population centres.
Greg Hutchinson, Executive Chair
“The completion of clinician training in NSW is a positive step in Emyria’s national expansion efforts. We are well-positioned to be able to deliver new therapies for the many people suffering complex mental health conditions who need access to treatment. With the Sydney clinic opening on track for Q3 CY2026, we are also pleased to confirm that we are delivering in line with our stated corporate milestones.”
Once the Sydney clinic opens, Emyria will operate clinical services in four states. This national footprint strategy supports patient access, data collection across diverse populations, and operational leverage as the company scales its service delivery model.
The next major ASX story will hit our subscribers first
Key milestones and timeline
The Sydney clinic opening is targeted for Q3 CY2026, providing investors with a clear near-term catalyst. Three key operational elements are confirmed as progressing:
- Clinician training completed
- Medication secured
- Fit-out requirements being finalised
This announcement serves as an execution checkpoint for investors tracking corporate milestones. The company is advancing operational readiness in parallel with its stated timeline, reducing the risk of launch delays. The Q3 CY2026 opening will mark Emyria’s entry into Australia’s largest state market and provide visibility on revenue contribution from the expanded clinical network.
Investors exploring the financial mechanics behind the Empax model can find our deep-dive into Emyria’s path to clinic-level breakeven, which covers the Perth clinic’s 30-dosing-day milestone, the three active reimbursement pathways, and the network capacity assumptions underpinning the broader national rollout.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive market-moving announcements the moment they break, before the market reacts.